About H.-Hartziekenhuis Roeselare-Menen vzw
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Pfizer
10
Celgene
5
Boston Scientific Corporation
2
Shire
2
Bavarian Nordic
1
Karyopharm Therapeutics Inc
1
Ocera Therapeutics
1
Onconova Therapeutics, Inc.
1
Sunesis Pharmaceuticals
1
Vascutek Ltd.
1
sigma-tau i.f.r. S.p.A.
1
Clinical Trials at H.-Hartziekenhuis Roeselare-Menen vzw
During the past decade, H.-Hartziekenhuis Roeselare-Menen vzw conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 12 clinical trials were completed, i.e. on
average, 400% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
2005-04-08
2009-09-07
Completed
829
Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas
2006-03-01
2008-09-01
Completed
191
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
2008-02-05
2015-05-27
Completed
502
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
2008-06-01
2013-08-01
Terminated
901
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
2008-01-01
2012-11-01
Terminated
1,100
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
2008-08-21
2016-07-14
Completed
1,623
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
2009-03-01
2013-04-09
Completed
861
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
2009-09-30
2017-11-02
Completed
1,199
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "H.-Hartziekenhuis Roeselare-Menen vzw" #1 sponsor was "Pfizer" with 10 trials, followed by "Celgene" with 5 trials
sponsored, "Boston Scientific Corporation" with 2 trials sponsored, "Shire" with 2 trials sponsored and "Bavarian Nordic"
with 2 trials sponsored. Other sponsors include 1 different institutions and
companies that sponsored additional 11 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "H.-Hartziekenhuis Roeselare-Menen vzw"
#1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator, "Pharmaceutical Research Associates" with 1 trials as a collaborator and "The Leukemia and Lymphoma Society" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 7 trials.
Clinical Trials Conditions at H.-Hartziekenhuis Roeselare-Menen vzw
According to Clinical.Site data, the most researched conditions in "H.-Hartziekenhuis Roeselare-Menen vzw" are
"Ulcerative Colitis" (6 trials), "Alzheimer Disease" (3 trials), "Myelodysplastic Syndromes" (2 trials), "Abdominal Aortic Aneurysms (AAA)" (1 trials) and "Acute Myeloid Leukemia" (1 trials). Many other conditions were trialed in "H.-Hartziekenhuis Roeselare-Menen vzw" in a lesser frequency.
Clinical Trials Intervention Types at H.-Hartziekenhuis Roeselare-Menen vzw
Most popular intervention types in "H.-Hartziekenhuis Roeselare-Menen vzw" are "Drug" (22 trials), "Biological" (2 trials), "Device" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (6 trials), "Rituximab" (3 trials), "CP-690,550" (2 trials), "Gemcitabine" (2 trials) and "bapineuzumab" (2 trials). Other intervention names were less common.
Clinical Trials Genders at H.-Hartziekenhuis Roeselare-Menen vzw
The vast majority of trials in "H.-Hartziekenhuis Roeselare-Menen vzw" are
24 trials for "All" genders and 2 trials for "Male" genders.
Clinical Trials Status at H.-Hartziekenhuis Roeselare-Menen vzw
Currently, there are NaN active trials in "H.-Hartziekenhuis Roeselare-Menen vzw".
undefined are not yet recruiting,
1 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 17 completed trials in H.-Hartziekenhuis Roeselare-Menen vzw,
undefined suspended trials,
and 6 terminated clinical trials to date.
Out of the total trials that were conducted in H.-Hartziekenhuis Roeselare-Menen vzw, 1 "Phase 1"
clinical trials were conducted, 3 "Phase 2" clinical
trials and 19 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 1 trials that are defined as “Not Applicable".